Dacarbazine Dosing Schedule for Melanoma

Evidence-Based Preferred Schedule

• The National Comprehensive Cancer Network recommends single-dose dacarbazine (850-1000 mg/m² every 3 weeks) as the current standard reference therapy for advanced melanoma, delivering equivalent efficacy to multiple-dose schedules with response rates of 10-20% 1, 2, 3

Clinical Context: Dacarbazine's Current Role

• The American Society of Clinical Oncology recommends ipilimumab plus nivolumab, nivolumab monotherapy, or pembrolizumab as first-line therapy for BRAF wild-type metastatic melanoma 4, 5
• The American Society of Clinical Oncology recommends dabrafenib plus trametinib, encorafenib plus binimetinib, or vemurafenib plus cobimetinib as first-line therapy for BRAF V600 mutant metastatic melanoma 4, 6

Combination Regimens Are Not Recommended

• The National Comprehensive Cancer Network states that dacarbazine-based combination chemotherapy or biochemotherapy does not improve survival compared to dacarbazine alone and increases toxicity 1, 2, 3

Expected Outcomes with Dacarbazine

• The overall response rate with dacarbazine monotherapy is 10-20% 1, 2, 3
• The median response duration with dacarbazine monotherapy is 3-4 months 1
• The median overall survival with dacarbazine monotherapy is 6-9 months historically 10

Critical Caveat

• The American Society of Clinical Oncology recommends that dacarbazine should only be considered when modern immunotherapy and targeted therapy are contraindicated, unavailable, or after progression on these agents 4, 5